An interventional study of ISET® - Isolation by Size of Tumor cells and ISET® - Isolation by Size of Tumor cells in Bronchial Cancer, sponsored by Fondation Hôpital Saint-Joseph. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-23.
Sponsored by Fondation Hôpital Saint-Joseph · Not applicable, Interventional, and Diagnostic
Among 19 studies in Carcinoma, Bronchogenic with a site in France — 4 open to participants now, 7 under way, 1 of them phase 3. Carcinoma, Bronchogenic · France.
Among the 19 studies in Carcinoma, Bronchogenic with a site in France, this one is the 12th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2016, is one of 5 with no phase, and was the 6th registered.
66 studies on the registry are indexed under Carcinoma, Bronchogenic; 12 are open to participants now.
Browse Carcinoma, Bronchogenic studies →4 of the 19 studies in Carcinoma, Bronchogenic with a site in France are open now. Recruiting first, the newest first:
University Hospital, Angers · Sites in France
Ages 18+ · Healthy volunteers
Institut du Cancer de Montpellier - Val d'Aurelle · Sites in France
Ages 18+
Eli Lilly and Company · Sites in France, United States, Australia and 26 more countries
Ages 18+
Turning Point Therapeutics, Inc. · Sites in France, United States, Australia and 16 more countries
Ages 12+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 12 Carcinoma, Bronchogenic studies recruiting now, 11 (92%) set no upper age limit and 1 (8%) stops at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 2
First in 2012; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 102 across 50 interventional studies indexed under Carcinoma, Bronchogenic.
Median enrollment 216 across the 12 interventional studies, 200 across the 7 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
Fondation Hôpital Saint-Joseph is the lead sponsor of 346 studies on the registry; 51 are open to participants now.
Fondation Hôpital Saint-Joseph has 1 study filed under Carcinoma, Bronchogenic — fewer than ten, so there is no comparison to draw.
1 of the studies in Carcinoma, Bronchogenic with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Carcinoma, Bronchogenic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The pronostic value of Circulating Tumoral Cells(CTC) 's dosage by the method ISET® (tumoral cell isolation by size) in patients with bronchial cancer was previously demonstrated.
However, no kinetic study was ever realized to study the value of the CTC as predictive indicator of answer to the therapy. This project plans to study patients in an early stage and patients at advance stage locally moved forward or metastatic of the disease by evaluation of the presence and the number of CTC before every cure. This collaborative and original study should allow to refine the diagnoses of answer and to plan the possible relapses what would allow a premature institution of the treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Early stage which can benefit from a surgical resection. A taking will be made in preoperative then in every consultation of follow-up after the intervention
Diagnostic Test: ISET® - Isolation by Size of Tumor cells
Patients locally moved forward or at a metastatic stage handled by chemotherapy
Diagnostic Test: ISET® - Isolation by Size of Tumor cells
early stage bronchial cancer patient will have a blood collection
advanced stage bronchial cancer patient will have a blood collection
numeration of CTC (circulant tumoral cell)
Time frame: Day 1
Ran from Mar 2016 to primary completion in Nov 2018, 32 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondation Hôpital Saint-Joseph →